Urinary Sodium-To-Potassium Ratio Is A Dual Indicator Of Hypertension And Current Disease Activity In Patients With Rheumatoid Arthritis: A Cross-Sectional Study In The KURAMA Cohort Database

Hiroto Minamino
Kyoto university

Masao Katsushima
Kyoto University

Motomu Hashimoto (✉ mohashim@kuhp.kyoto-u.ac.jp)
Kyoto University https://orcid.org/0000-0002-9241-060X

Yoshihito Fujita
Kyoto University

Tamami Yoshida
Kyoto Prefectural University of Medicine: Kyoto Furitsu Ika Daigaku

Kaori Ikeda
Kyoto University

Nozomi Isomura
Kyoto university

Yasuo Oguri
Kyoto university

Wataru Yamamoto
Kurashiki Sweet Hospital

Ryu Watanabe
Kyoto university

Kosaku Murakami
Kyoto university

Koichi Murata
Kyoto university

Kohei Nishitani
Kyoto university

Masao Tanaka
Kyoto university
Research article

Keywords: Urinary sodium-to-potassium ratio, Rheumatoid arthritis, Disease activity, Blood pressure, Hypertension, Sodium intake, Sodium restriction, Potassium intake

DOI: https://doi.org/10.21203/rs.3.rs-130990/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Excessive salt intake is thought to exacerbate both development of hypertension and autoimmune diseases in animal models, but the clinical impact of excessive salt in rheumatoid arthritis (RA) patients is still unknown. We performed a cross-sectional study to clarify the associations between salt load index (urinary sodium-to-potassium ratio (Na/K ratio)), current disease activity and hypertension in an RA population.

Methods: Three hundred thirty-six participants from our cohort database (KURAMA) were enrolled. We used the spot urine Na/K ratio as a simplified index of salt loading, and used the 28-Joint RA Disease Activity Score (DAS28-ESR) as an indicator of current RA disease activity. Using these indicators, we evaluated statistical associations between urinary Na/K ratio, DAS28-ESR and prevalence of hypertension.

Results: Urinary Na/K ratio was positively associated with measured systolic and diastolic blood pressure and also with prevalence of hypertension even after covariate adjustment (OR 1.30, \(p < 0.001\)). In addition, increased urinary Na/K ratio was significantly and positively correlated with DAS28-ESR in multiple regression analysis (estimate 0.12, \(p < 0.001\)), as was also the case in gender-separated and prednisolone-separated sub-analyses.

Conclusion: Urinary Na/K ratio was independently associated with current disease activity as well as with prevalence of hypertension in RA patients. Thus, dietary modifications such as salt restriction and potassium supplementation may well attenuate both disease activity and hypertension in RA patients.

Background

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by articular destruction and increased risk of comorbidity and mortality [1]. Over the past decades, clinical outcomes of RA have been dramatically improved by new therapeutics such as biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors [2, 3]. Despite such therapy, some patients continue to exhibit sustained high disease activity, which suggests involvement of unknown genetic or environmental factors.

A number of studies have reported that environmental factors participate in the pathogenesis of RA, including smoking, poor dental care, microbial imbalance and poor dietary habits [4, 5]. Recently, in experimental animal models, excessive salt intake has been implicated in the development of autoimmune diseases (i.e., RA, systemic lupus erythematosus, multiple sclerosis and Crohn’s disease) [6, 7]. In addition, excessive salt loading promotes pro-inflammatory responses in RA patients by affecting various types of immune cells [5, 6], and dietary salt presents a dose-dependent risk for the emergence of self-reported RA [8]. However, the clinical association between high salt intake and current disease activity of RA is still unclear.
Previous epidemiological studies have used various methods for estimating daily salt intake, which include Kawasaki’s formula and Tanaka’s formula [9, 10]. Recently, clinical evidence has emerged suggesting that the urinary sodium-to-potassium (Na/K) ratio is a useful index of dietary salt loading [11, 12]. Urinary Na/K ratio has a stronger correlation with blood pressure (BP) levels than Tanaka’s formula, and is used as a simple indicator of hypertension in the general population. However, so far there have been only small-scale studies using the urinary Na/K ratio for evaluation of clinical characteristics in an RA population [13].

In the present study, we used the spot urine Na/K ratio as a simplified index of salt loading, and assessed statistical associations between the urinary Na/K ratio and RA disease activity as well as between the urinary Na/K ratio and hypertension in RA patients.

Methods

Study design and participants

We conducted a cross-sectional study of RA patients who participated in the Kyoto University Rheumatoid Arthritis Management Alliance cohort (KURAMA cohort study) [14, 15]. The cohort was founded in May 2011 on the principle of appropriate control and improved prognosis for RA patients at the Center for Rheumatic Diseases in Kyoto University Hospital. A total of 441 RA outpatients who visited the hospital between May 1 and November 30, 2016 and who fulfilled the 2010 American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) classification were included [16]. Of the 441 participants, we excluded those with the following conditions: unsuccessful measurement of clinical parameters related to this study and lack of a complete dataset of body composition (n = 70); those with confounding conditions or treatments such as dialysis, hepatitis, sex-hormone replacement or suppression therapy and psychiatric disorders (n = 35) were also excluded. The remaining 336 participants were subjected to the analysis. All study procedures were in accordance with the Declaration Helsinki and were approved by the ethics committee of Kyoto University Graduate School and Faculty of Medicine (Approval number: R0357). In all cases, patient consent was obtained prior to sample and data collection.

Analysis of urine samples

Spot urine samples were collected and stored at −80 °C. The concentrations of urinary sodium (Na), potassium (K) and Creatinine (Cre) were measured using Electrolyte Analyzer and enzymatic method, respectively. (LSI Medience Co., Tokyo, Japan). Estimated daily salt intake was calculated using following Tanaka’s formula, which includes urinary Na, Cre, body weight, height and age [10]: Daily salt intake: 21.98×[Na (mEq/l) × 24-h Cre excretion/[Cre (mg/dl) × 10]]0.392×0.0585. 24-h Cre excretion was calculated using following formula: height (cm) × 16.14 + body weight (kg) × 14.89 – age × 2.04–2444.45.

RA-related factors and other clinical parameters
Disease activity and physical disability of RA was assessed using the following parameters: the 28-Joint RA Disease Activity Score (DAS28-ESR), the health assessment questionnaire-disability index (HAQ) and Steinbrocker's stage and class. The following laboratory data were also evaluated: C-reactive protein (CRP), serum Creatinine (Cre), estimated glomerular filtration (eGFR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP antibody), and matrix metalloproteinase-3 (MMP-3). Information on current RA therapeutics including use of methotrexate (MTX), prednisolone (PSL) and biological agents was extracted from the medical records.

Branchial blood pressure was measured after a few minutes rest in the sitting position by automatic digital monitor. Hypertension was defined by antihypertensive medication use, systolic blood pressure (SBP) $\geq 140$ mmHg or diastolic blood pressure (DBP) $\geq 90$ mmHg.

**Statistical analysis**

To analyze tertiles stratified by urinary Na/K level, a Cochran-Armitage trend test for categorical variables and a Jonckheere-Terpstra trend test for continuous variables was performed. To determine the relationship between blood pressure and urinary Na/K, urinary Na/K, SBP and DBP were compared by use of Spearman's rank correlation coefficient. Multivariate analysis was used to assess the association between the prevalence of hypertension and urinary Na/K. Dummy variables were constructed as follows: 0 = without hypertension, 1 = with hypertension, and multivariate logistic analysis was performed with adjustment for variables known to be associated with hypertension, including sex, age and smoking status. To assess the association between RA disease activity and urinary Na/K, multiple linear regression analysis was carried out with adjustment for covariates known to be associated with disease activity including sex, age, RF, anti-CCP antibody, smoking, current therapeutics (use of MTX, PSL and biological agents), eGFR and BMI [17]. Because PSL use and sex difference may be a confounding factors for both disease activity and urinary Na/K, additional multivariate analysis that did not include PSL use or sex difference was performed. Statistical significance was determined by use of JMP 14.0.0 software (SAS Institute Inc., Cary, NC, USA) and SPSS Statistics 26 software (IBM, Armonk, NY, USA); the level of significance was set at $P = 0.05$. 
Table 1
Clinical characteristics of study population (n = 336)
Continuous variables are presented as mean (± standard deviation) and categorical variables are presented as numbers (%). Data on RA-related parameters are expressed as median (range).

| Age, years | 61.8 ± 12.0 |
|------------|-------------|
| Male, n (%)| 57 (17.0)   |
| BMI, kg/m² | 22.7 ± 3.7  |
| Smoking status, n (%) | 28 (8.3) |

**RA-related parameters**

| Duration, years | 10.6 ± 9.6 |
| RF, IU/mL       | 38.5 (0-2833.6) |
| Anti-CCP antibody, U/mL | 50.45 (0.6–3260) |
| MMP-3, ng/mL    | 56.8 (18.2-633.6) |
| CRP, mg/dL      | 0.1 (0.1–9.6) |
| DAS28-ESR       | 2.4 (0.78–7.20) |
| HAQ score       | 0.25 (0-2.50) |
| Stage*          | 2.38 ± 1.16 |
| Class*          | 1.52 ± 0.60 |

**Laboratory data**

| Serum Cre, mg/dL | 0.69 ± 0.20 |
| eGFR, ml/min/1.73m² | 74.6 ± 18.0 |

**Blood pressure**

| SBP (Branchial), mmHg | 122.9 ± 17.4 |
| DBP (Branchial), mmHg | 70.5 ± 11.8 |
| Hypertension, n (%)   | 110 (32.7) |

Abbreviations: BMI Body mass index, RF rheumatoid factor, anti-CCP antibody anti-cyclic citrullinated peptide antibody, MMP-3 matrix metalloproteinase 3, CRP C-reactive protein, DAS28-ESR 28-joint disease activity score using erythrocyte sedimentation, HAQ health assessment questionnaire, Cre creatinine, eGFR estimated glomerular filtration, SBP systolic blood pressure, DBP diastolic blood pressure, Na sodium, K potassium, MTX methotrexate, csDMARD conventional synthetic disease modifying anti-rheumatic drugs, tsDMARD targeted synthetic DMARD, PSL prednisolone.

* Stage and Class: Steinbrocker's classification
### Results

#### Characteristics of study participants

The baseline characteristics of the 336 patients with RA are shown in Table 1. The mean age and the average RA duration were 61.8 years and 10.6 years, respectively. Compared to other reports, current RA activity measured by DAS28-ESR was generally low, possibly due to intensive treatments including biologic agents [18]. Indicators of salt intake including urinary Na/K ratio and estimated daily salt intake were similar compared to those in other reports [8, 13]. MTX, biological agent and PSL were used in 73.2%, 51.8%, and 20.8% of RA patients, respectively.

#### Comparison of characteristics in urinary Na/K ratio tertiles

To clarify the effect of the Na/K ratio on RA-related and hypertension-related factors, RA patients were stratified into tertiles by Na/K ratio, and characteristics were compared among the three groups. As urinary Na/K was increased, the prevalence of hypertension and measured value of blood pressure, both

| Age, years | 61.8 ± 12.0 |
|-----------|-------------|
| Urinalysis |             |
| Cre, mg/dL | 93.9 ± 63.9 |
| Na, mEq/L  | 102.8 ± 51.7|
| K, mEq/L   | 49.9 ± 29.9 |
| Na/K ratio | 2.60 ± 1.68 |
| Estimated daily salt intake, g | 7.80 ± 2.20 |

| Current RA therapeutics |         |
|-------------------------|---------|
| MTX use, n (%)          | 246 (73.2) |
| Other cs DMARDs use, n (%) | 116 (34.5) |
| Biological agent use, n (%) | 174 (51.8) |
| PSL use, n (%)          | 70 (20.8) |

Abbreviations: BMI Body mass index, RF rheumatoid factor, anti-CCP antibody anti-cyclic citrullinated peptide antibody, MMP-3 matrix metalloproteinase 3, CRP C-reactive protein, DAS28-ESR 28-joint disease activity score using erythrocyte sedimentation, HAQ health assessment questionnaire, Cre creatinine, eGFR estimated glomerular filtration, SBP systolic blood pressure, DBP diastolic blood pressure, Na sodium, K potassium, MTX methotrexate, csDMARD conventional synthetic disease modifying anti-rheumatic drugs, tsDMARD targeted synthetic DMARD, PSL prednisolone.

* Stage and Class: Steinbrocker's classification
systolic and diastolic, also increased (Table 2). The current RA disease activity scores including DAS28-ESR and DAS28-CRP also increased significantly as urinary Na/K increased. Age, BMI, eGFR and the percentage of males also increased along with the Na/K ratio. Regarding RA therapeutics, as the urinary Na/K ratio increased, the percentage of MTX use decreased while the percentage of PSL use increased.
Table 2
Characteristics of RA patients stratified by urinary Na/K ratio

Continuous variables are presented as mean (± standard deviation) and categorical variables are presented as numbers (%).

|                              | Tertile 1 | Tertile 2 | Tertile 3 | P value * |
|------------------------------|-----------|-----------|-----------|-----------|
| urinal Na/K ratio            | < 1.71    | 2.94 <    |           |           |
| (N = 336)                    | n = 112 (33.3%) | n = 112 (33.3%) | n = 112 (33.3%) |           |
| Age, year                    | 60.0 ± 13.2 | 62.4 ± 11.8 | 63.1 ± 11.0 | 0.143     |
| Male sex, n (%)              | 10 (8.92) | 22 (19.64) | 25 (22.32) | 0.001     |
| Body mass index, kg/m²       | 22.0 ± 3.1 | 22.6 ± 3.7 | 23.4 ± 4.1 | 0.011     |
| Smoking habit, n (%)         | 7 (6.25)  | 11 (9.82)  | 10 (8.93)  | 0.547     |
| Daily salt intake (g/day)    | 6.09 ± 1.36 | 7.67 ± 1.44 | 9.66 ± 2.04 | < 0.001   |
| Laboratory data              |           |           |           |           |
| Serum Cre, mg/dL             | 0.69 ± 0.16 | 0.72 ± 0.27 | 0.66 ± 0.16 | 0.081     |
| eGFR, ml/min/1.73m²          | 72.9 ± 18.2 | 73.0 ± 18.3 | 77.8 ± 17.2 | 0.010     |
| CRP, mg/dL                   | 0.32 ± 0.73 | 0.33 ± 0.65 | 0.45 ± 1.19 | 0.460     |
| RF, IU/mL                    | 100.3 ± 302.5 | 142.5 ± 279.4 | 131.4 ± 289.0 | 0.246     |
| anti-CCP antibody, U/mL      | 201.8 ± 435.8 | 242.8 ± 446.3 | 223.5 ± 444.2 | 0.216     |
| MMP-3, ng/mL                 | 73.8 ± 73.7 | 93.5 ± 86.0 | 96.3 ± 105.2 | 0.302     |
| RA disease characteristics   |           |           |           |           |
| Disease duration, year       | 9.66 ± 9.62 | 10.91 ± 9.82 | 11.16 ± 9.32 | 0.117     |
| DAS28-ESR                    | 2.40 ± 0.83 | 2.53 ± 0.96 | 2.74 ± 1.08 | 0.025     |
| DAS28-CRP                    | 1.92 ± 0.73 | 2.01 ± 0.79 | 2.22 ± 1.00 | 0.042     |
| HAQ                          | 0.37 ± 0.48 | 0.48 ± 0.57 | 0.52 ± 0.66 | 0.202     |
| Stage                        | 2.22 ± 1.14 | 2.45 ± 1.14 | 2.48 ± 1.19 | 0.094     |
| Class                        | 1.45 ± 0.57 | 1.60 ± 0.62 | 1.52 ± 0.60 | 0.386     |
| Blood pressure               |           |           |           |           |
| SBP (Branchial), mmHg        | 120.4 ± 16.5 | 121.2 ± 16.4 | 126.9 ± 18.5 | 0.009     |
| DBP (Branchial), mmHg        | 69.2 ± 10.5 | 69.3 ± 11.3 | 72.9 ± 13.1 | 0.043     |
| Hypertension, n (%)          | 25 (22.3)  | 37 (33.0)  | 48 (42.9)  | 0.0011    |
| Tertile 1 | Tertile 2 | Tertile 3 |
|----------|----------|----------|
| Current RA therapeutics | | |
| MTX use, n (%) | 90 (80.3) | 80 (71.4) | 76 (67.9) | 0.035 |
| Biological agent use, n (%) | 63 (56.3) | 55 (49.1) | 56 (50.0) | 0.386 |
| Predonisolone use, n (%) | 17 (15.2) | 23 (20.5) | 30 (26.8) | 0.040 |

Abbreviations: RA rheumatoid arthritis, Cre creatinine, eGFR estimated glomerular filtration, RF rheumatoid factor, anti-CCP antibody anti-cyclic citrullinated peptide antibody, MMP-3 matrix metalloproteinase 3, DAS28-ESR 28-joint disease activity score using erythrocyte sedimentation, CRP C-reactive protein, HAQ health assessment questionnaire, MTX methotrexate.

*P*-values are calculated using Cochran-Armitage trend test for categorical variables and Jonckheere-Terpstra trend test for continuous variables

Urinary Na/K ratio is positively associated with measured blood pressure and prevalence of hypertension

Although urinary Na/K ratio is a well-known indicator of blood pressure levels in the general population [11, 12], whether this is true in RA patients is not known. The relationship between urinary Na/K and measured blood pressure was therefore examined in RA patients. A significant positive association between urinary Na/K and systolic blood pressure (\( \rho = 0.1516, p = 0.0054 \)) as well as between urinary Na/K and diastolic blood pressure (\( \rho = 0.1173, p = 0.0316 \)) was observed. (Fig. 1A and B) Furthermore, the urinary Na/K ratio of RA patients with hypertension was higher than that of RA patients without hypertension (Fig. 1C), and multivariate logistic analysis after adjustment for sex, age and smoking status revealed an independent and positive association between urinary Na/K and prevalence of hypertension in RA patients. (OR 1.30, 95% CI 1.11–1.52, \( p < 0.001 \)) (Table 3) These findings strongly suggest that urinary Na/K is an indicator of hypertension in RA patients as well as in the general population.
Table 3
Multivariate logistic analysis for the factors associated with hypertension

Results of multivariate logistic regression regarding the presence of hypertension in RA patients. We constructed dummy variables as follows: 0 = without hypertension and 1 = with hypertension, and logistic analysis was carried out with potential confounders including age, sex and current smoking status.

| variables     | OR   | 95% CI     | P value |
|---------------|------|------------|---------|
| Age (1 year)  | 1.10 | 1.06–1.13  | < 0.001 |
| Urinary Na/K ratio (1) | 1.30 | 1.11–1.52  | < 0.001 |
| Sex (male = 1, female = 0) | 1.97 | 1.01–3.83  | 0.046   |

Abbreviations: RA rheumatoid arthritis, OR odds ratio

Urinary Na/K ratio is independently associated with current RA disease activity

To determine whether urinary Na/K ratio contributes to current RA disease activity, we performed multiple regression analysis with DAS28-ESR as the dependent variable. After adjustment for covariates known to be related to disease activity, urinary Na/K ratio was found to be independently and positively associated with DAS28-ESR (estimate 0.12, p < 0.001) (Table 4). In addition, because use of PSL and sex difference may be a confounding factor affecting both disease activity and urinary Na/K [19], subgroup analysis was performed to account for use of PSL and sex difference. Urinary Na/K ratio remained independently associated with DAS28-ESR in gender-separated analysis (Supplementary Table S1) as well as in PSL-separated analysis (Supplementary Table S2). These results indicate that urinary Na/K ratio is an independent indicator associated with current RA disease activity.
Table 4
Multivariate analysis for independent factors associated with DAS28-ESR
Results of multiple regression analysis adjusted for urinary Na/K and other variables including sex, age, RF, anti-CCP antibody, smoking status, current therapeutics (the use of MTX, PSL and biological agents), eGFR and BMI.

| Dependent variables | Independent variables | Estimates | Std. Error | Lower  | Upper  | p-value  |
|---------------------|-----------------------|-----------|------------|--------|--------|----------|
| DAS28-ESR           | Sex (male)            | -0.58     | 0.14       | -0.85  | -0.31  | < 0.0001 |
|                     | Prednisolone (+)      | 0.48      | 0.12       | 0.23   | 0.72   | 0.0001  |
|                     | Urinary Na/K ratio    | 0.11      | 0.030      | 0.048  | 0.170  | 0.0004  |
|                     | age (1 year)          | 0.015     | 0.0046     | 0.0055 | 0.024  | 0.0016  |
|                     | RF (1 IU/mL)          | 0.00054   | 0.00019    | 0.00017| 0.00091| 0.0042  |
|                     | Biological agent (+)  | -0.23     | 0.098      | -0.42  | -0.033 | 0.021   |
|                     | Anti-CCP antibody (10 U/mL) | 0.0025 | 0.0012 | 0.00015 | 0.0048 | 0.037 |

Abbreviations: DAS28-ESR 28-joint Disease Activity Score using erythrocyte sedimentation rate, anti-CCP antibody anti-cyclic citrullinated peptide antibody, CI confidence interval.

Discussion
In the present study, we show a statistical correlation between RA disease activity and urinary Na/K ratio as well as between hypertension and urinary Na/K ratio. The Na/K ratio of spot urine was positively associated with systolic and diastolic BP, and was significantly associated with the prevalence of hypertension even after covariate adjustment. In addition, in multivariate analysis including RA related factors, urinary Na/K ratio was independently correlated with current disease activity score (DAS28-ESR). These results indicate that urinary Na/K ratio reflects not only hypertension but also current disease status in RA patients.

Our finding of a statistical association between urinary Na/K ratio and hypertension in RA patients corresponds to previous findings in the general population [11, 12, 19]. Abundant evidence has recently emerged indicating that both excess sodium and potassium deficit participate in the development of hypertension [20–22], and that the combined effect of higher sodium and lower potassium levels on BP is greater than that of either one alone [11, 23]. Similarly, the urinary Na/K ratio has a stronger statistical relationship with BP levels than that of either Na or K secretion alone [11, 24], and also associates with left ventricular hypertrophy and cardiovascular disease [25, 26]. In addition, dietary modifications that can reduce the urinary Na/K ratio are recommended as well-established nutritional therapies for hypertension,
such as salt restriction and increased potassium intake (i.e., a diet rich in fruits and vegetables) [27–29]. Considering these findings together, the urinary Na/K ratio may be useful as an indicator of hypertension in the RA population as it is in the general population; dietary modification strategies that reduce the urinary Na/K ratio in the general population may well benefit RA patients.

We also show a significant correlation between DAS28-ESR and urinary Na/K ratio. Urinary Na/K ratio is a strong indicator of hypertension, and is affected by both dietary salt and potassium as mentioned above. Recently, basic and clinical studies have reported that sodium and potassium are closely related to the immune system and RA development [7, 8, 30]. A high sodium concentration enhances differentiation of potentially pathogenic Th17 cells [31], promotes pro-inflammatory macrophage polarization [32], and reduces anti-inflammatory responses of Treg cells and M2 macrophages [33, 34]. In animal models, mice with collagen-induced arthritis (CIA) on high salt diet show severe joint inflammation that is accelerated by increased Th-17 cell differentiation [35]. In epidemiological studies, dietary sodium has a dose-dependent relationship with the emergence of RA [8], and high salt intake combined with smoking results in increased risk for the appearance of anti-CCP antibodies [36]. In addition, a pilot study has shown that potassium supplementation improves joint pain in RA patients with hypokalemia [37]. Moreover, our group has previously reported that potassium-rich ingredients such as fruits and vegetables are significantly associated with lower RA disease activity [38]. In summary, the urinary Na/K ratio is an independent disease activity marker of RA, and increased Na intake and decreased K intake may contribute to RA pathogenesis.

In multivariate logistic analysis, other variables such as RF, anti-CCP antibody, age, sex and PSL use were also associated with DAS28-ESR. These results are in accordance with previous reports. High titers of RF or anti-CCP antibody are well-known to be unfavorable prognostic factors in RA [39], and female sex is independently associated with increased ESR levels in RA patients [40]. Long-term use of PSL potentially has multiple adverse effects, and is usually limited to patients with few therapeutic options or sustained high disease activity.

The present study combines a large-scale cohort data set with a simplified predictor of hypertension. Among several estimation methods of daily salt intake, sodium excretion of 24-h urinary storage is the most reliable, but is inconvenient for large-scale surveys. The Na/K ratio of spot urine is closely correlated with that of 24-h urine collection [41], and has a stronger association with BP levels than Tanaka's formula [12]. The urinary Na/K ratio is thus a more suitable method for large sample size investigation.

There are several limitations in the present study. Our cross-sectional study does not imply causation, and the long-term effect of urinary Na/K on hypertension and RA disease activity is still unknown. Furthermore, the amount and sensitivity to salt intake differs by background including genetics and dietary habits [28]. In addition, there could be unknown confounding ingredients or nutrients in the diet of our study population. Finally, we did not adjust for certain clinical and lifestyle factors that might affect urinary Na/K ratio such as fasting time and seasonal variation [12].
Conclusions

In summary, this cross-sectional study revealed that the urinary Na/K ratio is significantly associated with RA disease activity as well as prevalence of hypertension. This result raises the possibility that the urinary Na/K ratio is an independent disease activity marker of RA and increased Na intake and decreased K intake contribute to pathogenesis of RA as well as hypertension (Fig. 2). Thus, nutritional strategies that reduce the urinary Na/K ratio such as salt restriction and potassium supplementation may be candidates for attenuating disease activity of RA as well as hypertension.

Abbreviations

RA: rheumatoid arthritis, KURAMA: Kyoto University Rheumatoid Arthritis Management Alliance cohort, Na: sodium, K: potassium, DAS28-ESR: 28-joint disease activity score using erythrocyte sedimentation, BP: blood pressure, HAQ: health assessment questionnaire, CRP: C-reactive protein, eGFR: estimated glomerular filtration, RF: rheumatoid factor, anti-CCP antibody: anti-cyclic citrullinated peptide antibody, MTX: methotrexate, PSL: prednisolone, SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: Body mass index

Declarations

Acknowledgments

We are grateful to Dr. Hidetaka Miyauchi for his valuable suggestions. We thank Ms. Sumie Nakagawa for management of blood specimens. We also thank Ms. Noriko Kitayama and Ms. Maki Yoneyama for support of the patients.

Funding

This study (KURAMA cohort study) is supported by a grant from Daiichi Sankyo Co. Ltd. The funder had no role in the design of the study, the collection or analysis of the data, the writing of the manuscript or the decision to submit the manuscript for publication.

Competing interests

M.H., K.M. (Murata), K.N., and M.T. (Tanaka) are members of a department that is financially supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Tanabe-Mitsubishi, Chugai, UCB Japan, Ayumi and Asahi-Kasei). The KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd. M.H. receives grants and/or speaker fees from Bristol-Myers, Eisai, Eli Lilly, and Tanabe Mitsubishi. K.N. received a research grant from Asahi-Kasei Pharma. H.I. receives a research grant and/or speaker fee from Bristol-Myers, Kyocera, and Asahi-Kasei. K.O. has received research grants and/or speaker’s fee from Abbvie, Actelion, Asahikasei Pharma, Astellas, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Janssen, JB, Mitsubishi Tanabe, Nippon
Kayaku, Nippon Shinyaku, Novartis, Sanofi and Takeda. S.M. receives grants and/or speaker fees from Daiichi Sankyo, Asahi-Kasei, Chugai, Ayumi, and Tanabe Mitsubishi. A.M. has received speaking fees and/or research grants from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Pfizer Inc., UCB Japan, AbbVie G.K., Asahi Kasei Pharma and Chugai Pharmaceutical Co. Ltd. H.M., M.K., T.Y., Y.F., K.I., N.I., Y.O., W.Y., K.M. (Murakami), H.A., and N.I. declare no conflicts of interest. The sponsors had no role in the design of the study, the collection or analysis of the data, the writing of the manuscript or the decision to submit the manuscript for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.

**Author Contributions**

H.M., M.H., and Y.F. are responsible for study conception and design. H.M. and M.K contributed to interpretation of the data, drafted the manuscript, and revised the manuscript. T.Y. contributed to acquisition of the data. M.H. and Y.F contributed to interpretation of the data and revised the manuscript. K.I., N.I., Y.O., M.S., W.Y, R.W., K.M.(Murakami), K.M. (Murata), K.N., M.T., H.I., K.O., S.M., N.I., and A.M. contributed to supervision of the manuscript for intellectual content. All authors have approved the final manuscript for publication and have agreed to be personally accountable for the authors’ contributions.

**Availability of data and materials**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

This study was conducted according to the Declaration of Helsinki and were approved by the ethics committee of Kyoto University Graduate School and Faculty of Medicine (Approval number: R0357). In all cases, patient consent was obtained prior to sample and data collection.

**Consent for publication**

Not applicable

**References**

1. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet. 2017;389(10086):2328–37.

2. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken).
3. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.

4. Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2017;17(1):60–75.

5. Sharif K, Amital H, Shoenfeld Y. The role of dietary sodium in autoimmune diseases: The salty truth. Autoimmun Rev. 2018;17(11):1069–73.

6. Muller DN, Wilck N, Haase S, Kleinewietfeld M, Linker RA. Sodium in the microenvironment regulates immune responses and tissue homeostasis. Nat Rev Immunol. 2019;19(4):243–54.

7. Scrivo R, Perricone C, Altobelli A, Castellani C, Tinti L, Conti F, et al. Dietary habits bursting into the complex pathogenesis of autoimmune diseases: The emerging role of salt from experimental and clinical studies. Nutrients. 2019;11(5).

8. Salgado E, Bes-Rastrollo M, de Irala J, Carmona L, Gomez-Reino JJ. High sodium intake is associated with self-reported rheumatoid arthritis: A cross sectional and case control analysis within the SUN cohort. Med (Baltim). 2015;94(37):e924.

9. Kawano Y, Tsuchihashi T, Matsuura H, Ando K, Fujita T, Ueshima H, et al. Report of the working group for dietary salt reduction of the Japanese Society of Hypertension: (2) Assessment of salt intake in the management of hypertension. Hypertens Res. 2007;30(10):887–93.

10. Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens. 2002;16(2):97–103.

11. Mente A, O'Donnell MJ, Rangarajan S, McQueen MJ, Poirier P, Wielgosz A, et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med. 2014;371(7):601–11.

12. Tabara Y, Takahashi Y, Kumagai K, Setoh K, Kawaguchi T, Takahashi M, et al. Descriptive epidemiology of spot urine sodium-to-potassium ratio clarified close relationship with blood pressure level: the Nagahama study. J Hypertens. 2015;33(12):2407–13.

13. Carranza-Leon D, Octaria R, Ormseth MJ, Oeser A, Solus JF, Zhang Y, et al. Association between urinary sodium and potassium excretion and blood pressure and inflammation in patients with rheumatoid arthritis. Clin Rheumatol. 2018;37(4):895–900.

14. Minamino H, Katsushima M, Yoshida T, Hashimoto M, Fujita Y, Shirakashi M, et al. Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database. PLoS One. 2020;15(3):e0229998.

15. Murata K, Ito H, Hashimoto M, Nishitani K, Murakami K, Tanaka M, et al. Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. Int J Rheum Dis. 2019;22(6):1084–93.

16. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism
17. Masdottir B, Jonsson T, Manfredsdottir V, Vikingsson A, Brekkan A, Valdimarsson H. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology. 2000;39(11):1202–5.

18. Giles JT, Allison M, Bingham CO 3rd, Scott WM Jr, Bathon JM. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum. 2009;61(9):1248–56.

19. Hedayati SS, Minhajuddin AT, Ijaz A, Moe OW, Elsayed EF, Reilly RF, et al. Association of urinary sodium/potassium ratio with blood pressure: sex and racial differences. Clin J Am Soc Nephrol. 2012;7(2):315–22.

20. Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356(19):1966–78.

21. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation. 2000;101(8):856–61.

22. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA. 1997;277(20):1624–32.

23. Morris RC Jr, Sebastian A, Forman A, Tanaka M, Schmidlin O. Normotensive salt sensitivity: effects of race and dietary potassium. Hypertension. 1999;33(1):18–23.

24. Group ICR. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group BMJ. 1988;297(6644):319–28.

25. Cook NR, Obarzanek E, Cutler JA, Buring JE, Rexrode KM, Kumanyika SK, et al. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. Arch Intern Med. 2009;169(1):32–40.

26. Rodriguez CJ, Bibbins-Domingo K, Jin Z, Daviglus ML, Goff DC Jr, Jacobs DR Jr. Association of sodium and potassium intake with left ventricular mass: coronary artery risk development in young adults. Hypertension. 2011;58(3):410–6.

27. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47(2):296–308.

28. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3–10.

29. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279(11):839–46.
30. Sundstrom B, Johansson I, Rantapaa-Dahlqvist S. Interaction between dietary sodium and smoking increases the risk for rheumatoid arthritis: results from a nested case-control study. Rheumatology. 2015;54(3):487–93.

31. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature. 2013;496(7446):518–22.

32. Hucke S, Eschborn M, Liebmann M, Herold M, Freise N, Engbers A, et al. Sodium chloride promotes pro-inflammatory macrophage polarization thereby aggravating CNS autoimmunity. J Autoimmun. 2016;67:90–101.

33. Binger KJ, Gebhardt M, Heinig M, Rintisch C, Schroeder A, Neuhofer W, et al. High salt reduces the activation of IL-4- and IL-13-stimulated macrophages. J Clin Invest. 2015;125(11):4223–38.

34. Hernandez AL, Kitz A, Wu C, Lowther DE, Rodriguez DM, Vudattu N, et al. Sodium chloride inhibits the suppressive function of FOXP3 + regulatory T cells. J Clin Invest. 2015;125(11):4212–22.

35. Jung SM, Kim Y, Kim J, Jung H, Yi H, Rim YA, et al. Sodium Chloride Aggravates Arthritis via Th17 Polarization. Yonsei Med J. 2019;60(1):88–97.

36. Jiang X, Sundstrom B, Alfredsson L, Klareskog L, Rantapaa-Dahlqvist S, Bengtsson C. High sodium chloride consumption enhances the effects of smoking but does not interact with SGK1 polymorphisms in the development of ACPA-positive status in patients with RA. Ann Rheum Dis. 2016;75(5):943–6.

37. Rastmanesh R, Abargouei AS, Shadman Z, Ebrahimi AA, Weber CE. A pilot study of potassium supplementation in the treatment of hypokalemic patients with rheumatoid arthritis: a randomized, double-blinded, placebo-controlled trial. J Pain. 2008;9(8):722–31.

38. Murakami I, Murakami K, Hashimoto M, Tanaka M, Ito H, Fujii T, et al. Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis. PLoS One. 2020;15(2):e0228852.

39. Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther. 2017;19(1):68.

40. Siemons L, Ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC Musculoskelet Disord. 2014;15:368.

41. Iwahori T, Ueshima H, Miyagawa N, Ohgami N, Yamashita H, Ohkubo T, et al. Six random specimens of daytime casual urine on different days are sufficient to estimate daily sodium/potassium ratio in comparison to 7-day 24-h urine collections. Hypertens Res. 2014;37(8):765–71.